缬沙坦氢氯噻嗪治疗脑心综合征患者的临床效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinical effect of Valsartan Hydrochlorothiazide in the treatment of patients with cerebral-cardiac syndrome.Methods A total of 90 cases of patients diagnosed with cerebral-cardiac syndrome admitted to our hospital from January 2016 to January 2019 were selected as the research objects, who were divided into treatment group (45 cases) and control group (45 cases) according to random number table method，the control group was treated by regular treatment,the treatment group was treated by regular treatment combined with Valsartan Hydrochlorothiazide.The clinical efficacy, electrocardiograph (ECG) improvement, C-reactive protein (CRP), tumor necrosis factor(TNF-α) and interleukin-6 (IL-6) levels before and after treatment were compared between the two groups.Results The total effective rate and the ECG effective rate of the treatment group were higher than those of the control group,and the levels of CRP, IL-6 and TNF-α in the treatment group were lower than those of the control group, the differences were statistically significant(P<0.05).Conclusion Valsartan Hydrochlorothiazide can significantly reduce the CRP,TNF-α and IL-6 levels, which can improve the clinical curative effect of patients with cerebral-cardiac syndrome.

Key words： Valsartan Hydrochlorothiazide Cerebral-cardiac syndrome Clinical effect Inflammation factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	MA Chao
	WANG Cheng-gao
	YUAN Wen-Jin

Cite this article:

MA Chao,WANG Cheng-gao,YUAN Wen-Jin. Clinical effect of Valsartan Hydrochlorothiazide in the treatment of patients with cerebral-cardiac syndrome[J]. 中国当代医药, 2020, 27(12): 129-131转135.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I12/129

[1]	Idkaidek N，Agha N，Arafat T.Saliva versus plasma bioequivalence of valsartan/hydrochlorothiazide in humans：validation of classesⅡand Ⅳdrugs of the salivary excretion classification system[J].Drug Res，2018，68（1）：54-59.
[2]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病组.中国急性脑血管病诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[3]	魏勇.急性脑卒中患者发生脑心综合征的临床特点及对预后的影响[J].中国实用神经疾病杂志，2016，19（2）：97-99.
[4]	徐希平.心脑血管疾病药物研发的思考与对策[J].药学进展，2016，40（2）：81-82.
[5]	邓树荣，梁涛，李洪韬，等.急性脑血管病血清心肌酶变化的临床研究[J].广西医学，2004，26（9）：1315-1316.
[6]	王艳茹，周国亮，张月婵，等.50例急性重症脑梗死患者心电图分析[J].中国现代医生，2018，56（26）：46-48.
[7]	曾红科，叶珩，孙诚.脑心综合征145例临床分析[J].广东医学.1999.17（8）：614-616.
[8]	高文勇.脑心综合征研究进展[J].医学临床研究，2012，29（12）：2385-2386.
[9]	赵明伦.脑血管病的抢救与康复[M].北京：人民卫生出社，1998：222-223.
[10]	王娜，夏青，赵剑，等.AngⅡ/Ang-（1-7）/Mas系统通路与脑心综合征关系的实验研究[J].哈尔滨医科大学学报，2012，46（3）：207-211.
[11]	尹海峰.缬沙坦与非洛地平对照治疗高血压动脉硬化性脑梗死的疗效与药物经济学分析[J].山西医药杂志，2008，37（8）：722-724.
[12]	胡英，张鑫.急性脑卒中并发脑心综合征的临床特点[J].中国当代医药，2019，26（7）：102-104.
[13]	刘淑婷.急性脑血管病并发脑心综合征临床观察[J].中国药物与临床，2019，19（4）：610-611.
[14]	王拥军.血管紧张素受体拮抗剂在改善脑卒中患者预后中的作用[J].中华高血压杂志，2012，20（5）：411-413.
[15]	孙宁玲.血管紧张素受体拮抗剂对脑卒中预防及治疗作用的评价[J].中华高血压杂志，2010，18（10）：913-915.
[16]	唐启卫.缬沙坦对颈动脉不稳定斑块患者血清炎症介质及缺血性脑卒中复发的影响[J].临床荟萃，2007，22（11）：775-779.